These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11134267)

  • 1. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects.
    Ecder T; Schrier RW
    J Am Soc Nephrol; 2001 Jan; 12(1):194-200. PubMed ID: 11134267
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
    Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
    Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension in autosomal dominant polycystic kidney disease.
    Chapman AB; Gabow PA
    Kidney Int Suppl; 1997 Oct; 61():S71-3. PubMed ID: 9328971
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
    Rahbari-Oskoui F; Williams O; Chapman A
    Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular risk in polycystic kidney disease].
    Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
    G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on pathogenesis, management, and treatment of hypertension in autosomal dominant polycystic kidney disease.
    Helal I; Al-Rowaie F; Abderrahim E; Kheder A
    Saudi J Kidney Dis Transpl; 2017; 28(2):253-260. PubMed ID: 28352004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension in autosomal dominant polycystic kidney disease.
    Parfrey PS; Barrett BJ
    Curr Opin Nephrol Hypertens; 1995 Sep; 4(5):460-4. PubMed ID: 8564453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2016 May; 67(5):792-810. PubMed ID: 26530876
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
    Cerasola G; Li Vecchi M; Mulé G; Cottone S; Mangano MT; Andronico G; Contomo A; Parrino IA; Renda F; Pavone G; Scialabba A
    Contrib Nephrol; 1997; 122():22-7. PubMed ID: 9399032
    [No Abstract]   [Full Text] [Related]  

  • 10. [Renal manifestation of Autosomal Dominant Polycystic Kidney Disease].
    Galliani M; Chicca S; Vitaliano E; Di Lullo L; Giannakakis K; Paone A
    G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autosomal-dominant polycystic kidney disease and hypertension: a review.
    Florijn KW; van Saase JL; Breuning MH; Chang PC
    Contrib Nephrol; 1992; 97():71-92. PubMed ID: 1386018
    [No Abstract]   [Full Text] [Related]  

  • 13. Genesis and significance of hypertension in autosomal dominant polycystic kidney disease.
    Zeier M; Ritz E; Geberth S; Gonzalo A
    Nephron; 1994; 68(2):155-8. PubMed ID: 7830851
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
    Steinman TI
    Nephrol Dial Transplant; 2008 Feb; 23(2):431-3. PubMed ID: 18065782
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal volume in children with ADPKD: size matters.
    Chapman AB; Guay-Woodford LM
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):698-9. PubMed ID: 19339418
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and treatment of hypertension in polycystic kidney disease.
    Neumann J; Ligtenberg G; Klein IH; Blankestijn PJ
    Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):517-21. PubMed ID: 12187316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A; Elhassan E; Schrier RW
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular complications in autosomal dominant polycystic kidney disease.
    Ecder T
    Curr Hypertens Rev; 2013 Feb; 9(1):2-11. PubMed ID: 23971638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.